The use of recombinant human G-CSF in the treatment of propylthiouracil-induced agranulocytosis.
A 43-year-old female patient with Basedow-Graves' disease developed agranulocytosis in the eighth month of propylthiouracil therapy. After discontinuing the drug, a broad spectrum antibiotic regimen plus recombinant human granulocyte colony-stimulating factor (G-CSF), a human haematopoietic growth factor, were started. Her granulocyte count returned to normal with the second dose of G-CSF, and ulcerating pharyngitis improved rapidly. We think that in patients with propylthiouracil-induced agranulocytosis, G-CSF will reduce the risk and severity of infection, and should be accepted as a part of the standard therapy.
Altunbas
H
H
Department of Endocrinology and Metabolism, Akdeniz University School of Medicine, Turkey.
Yazicioglu
G
G
Balci
M K
MK
Karayalçin
U
U
Undar
L
L
D000328:Adult; D000380:Agranulocytosis / Q000139:chemically induced / Q000628:therapy*; D013956:Antithyroid Agents / Q000009:adverse effects; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006098:Granulocytes; D006111:Graves Disease / Q000150:complications / Q000628:therapy; D006801:Humans; D007958:Leukocyte Count; D011441:Propylthiouracil / Q000009:adverse effects; D011994:Recombinant Proteins; D016896:Treatment Outcome
D013956:Antithyroid Agents; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D011441:Propylthiouracil